Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis
Abstract
Vedolizumab is superior to placebo as induction and maintenance therapy for ulcerative colitis. Future studies are needed to define long-term efficacy and safety of this agent.
Keywords
systematic review
meta-analysis
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
review
humans
pubmed abstract
nih
national institutes of health
national library of medicine
prognosis
research support
non-u.s. gov't
Remission Induction
Antibodies
Monoclonal
Brian G Feagan
Humanized / therapeutic use*
Colitis
Ulcerative / drug therapy*
Gastrointestinal Agents / therapeutic use*
induction chemotherapy
maintenance chemotherapy
pmid:25844963
doi:10.1097/mib.0000000000000396
mahmoud h mosli
john k macdonald
Access
Citation
ID:
115341
References
Blockchain Verification
Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
115341
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
Creates 1,000,000 NFT tokens for this article
Token Features:
- ERC-1155 Standard NFT
- 1 Million Supply per Article
- Transferable via MetaMask
- Permanent Blockchain Record
Scan with Saymatik Web3.0 Wallet